Evaluation of Physical Properties and Usability of Brimonidine Tartrate Ophthalmic Solution for the Treatment of Glaucoma in Brand-name and Generic Drug Formulations-Reference-Cited by-同舟云学术

Evaluation of Physical Properties and Usability of Brimonidine Tartrate Ophthalmic Solution for the Treatment of Glaucoma in Brand-name and Generic Drug Formulations

Published:2023-08-10 Issue:8 Volume:49 Page:310-318
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

Author:

Akiyama Shigeo¹,Yoneda Masaaki²,Miyamoto Etsuko³,Maida Chieko⁴,Ishida Shiro⁵,Hori Yusuke¹,Doi Nobuyuki⁶

Affiliation:

1. Center for Experiential Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

2. Kyowa Pharmacy

3. Non Profit Organization Health & Welfare･Eco-Protect･Area Contribution･Refresh Education･Town Communication

4. Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokuriku University

5. Laboratory of Pharmaceutics, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University

6. Laboratory of Community Healthcare, Faculty of pharmacy, Takasaki University of Health and Welfare

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Link

https://www.jstage.jst.go.jp/article/jjphcs/49/8/49_310/_pdf

Reference21 articles.

1. 1）Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, Shiraga F, Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals, Jpn J Ophthalmol, 2019, 63, 26-33.

2. 3）Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM, Persistence and adherence with topical glaucoma therapy, Am J Ophthalmol, 2005, 140, 598-606.

3. 4）Schwartz GF, Quigley HA, Adherence and Persistence with Glaucoma Therapy, Surv Ophthalmol, 2008, 53, S57-S68.

4. 5）Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW, Compliance barrier in glaucoma: a systematic classification, J Glaucoma, 2003, 12, 393-398.

5. 6）和田智之, Burke JA, Wheeler LA, ブリモニジン酒石酸塩点眼液（アイファガン点眼液0.1％）の特徴, 医学と薬学, 2012, 67, 547-555.